MedTrace Logo

Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

NCT00856674 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-06-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in patients with IgA Nephropathy who have high levels of protein in the urine.

Conditions

Interventions

BIOLOGICAL

OPL-CCL2-LPM

CCL2-LPM intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg 2 doses one week apart

Sponsors & Collaborators

  • Osprey Pharmaceuticals USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Vincent Pichette, M.D., Ph.D. · Hopital Maisonneuve-Rosemont, Univeristy of Montreal

  • Michelle Hladunewich, M.D. · Sunnybrook Health Sciences Centre

  • Bryan Curtis, M.D. · Eastern Health, HSC, Memorial University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856674 on ClinicalTrials.gov